ADMANews Brief
By Basis Report Editorial · Updated March 31, 2026
UPDATE March 30: Cantor Fitzgerald downgraded ADMA Biologics to Neutral from Overweight, a direct blow to the bullish thesis this article advanced when ADMA's 11.6% single-session jump appeared to validate management's rebuttal of the Culper Research short report. The downgrade confirms what the price action has since made plain: ADMA shares are down 45.4% since the last earnings report, erasing the rebound and then some. Cantor cited the Culper controversy as a key factor — meaning a firm that had been a conviction bull on the name now views the risk/reward as balanced at best. The original framing — that the market had assessed the short-seller's claims and sided with ADMA — no longer holds. Sentiment has shifted from bullish to cautious, and a major sell-side endorsement is now off the table. Watch the next earnings print for any revision to IG product revenue guidance, which has been the core growth driver. A cut there would pressure the remaining bulls. Any further sell-side downgrades or coverage drops in the next 30 days would signal the Street is still de-risking the position.

ADMA Biologics Jumps 11.6% After Rejecting Culper Short Report

NEW YORK, March 28 —

ADMA Biologics (ADMA) rebounded 11.6% Friday after the plasma-derived immunotherapy company issued a formal denial of allegations published by short seller Culper Research, calling the claims "unsubstantiated, misleading and inaccurate."

The bounce does little to repair the damage accumulated since ADMA's last earnings report, with shares still off ~45.4% from that post-earnings level and trading at $9.25. The timing is particularly sharp: Cantor Fitzgerald downgraded ADMA from Overweight to Neutral one day before the rebuttal landed, cutting its bullish conviction just as the company needed sell-side cover most. At 6.7x forward P/E against $510mn in TTM revenue, ADMA trades cheap by biotech standards — but cheapness alone doesn't neutralize a credible short thesis. Culper's track record, and whether its specific allegations carry regulatory weight, will matter more to the next move than valuation multiples. The post-earnings decline suggests the market was already pricing in fundamental softness before Culper fired; the short report accelerates a debate that was already forming.

The binary setup here is unusually stark. If the SEC or FDA opens an inquiry prompted by Culper's report, the 11.6% bounce evaporates quickly and the stock revisits — or breaks — its post-earnings lows. If ADMA's rebuttal holds and no regulatory follow-through materializes, short covering could push shares meaningfully higher from current levels. The critical watch metric over the next 5–10 trading days is whether additional sell-side analysts revise ratings or price targets in either direction — a cluster of downgrades would confirm the Cantor move was an informed signal rather than coincidental timing. Equally, any silence from regulators after 10 trading days reduces the probability of a formal probe and tilts the near-term risk/reward toward holders. Absent a regulatory trigger, this resolves into a credibility contest between ADMA's management and Culper's research, with the stock as the scoreboard.

For a full fundamental breakdown — earnings estimates, revenue trajectory, and institutional positioning — generate a Basis Report on ADMA at /stock/adma.

Basis Report does not hold positions in securities discussed. This is not investment advice.